Targetted anti-tumor drug delivery systems

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 47/48 (2006.01) A61K 9/127 (2006.01) A61K 31/565 (2006.01) A61K 31/704 (2006.01) A61K 39/395 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2437768

Methods for treating proliferative diseases, especially breast cancers, comprising administering (1) a therapeutically effective amount of a liposomal anthracycline composition in association with (2) a therapeutically effective amount of an antibody directed against the extracellular domain of a growth factor receptor and optionally in association with (3) a therapeutically effective amount of an additional antineoplastic agent, are disclosed.

L'invention concerne des méthodes permettant de traiter des maladies prolifératives, notamment les cancers du sein, qui consiste à administrer 1) une quantité thérapeutiquement efficace d'une composition d'anthracycline liposomale associée à 2) une quantité thérapeutiquement efficace d'un anticorps dirigé contre le domaine extracellulaire d'un récepteur de facteur de croissance, et éventuellement à 3) une quantité thérapeutiquement efficace d'un agent antinéoplasique supplémentaire.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Targetted anti-tumor drug delivery systems does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targetted anti-tumor drug delivery systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targetted anti-tumor drug delivery systems will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1411960

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.